We are deeply grateful to the Giorgio Foundation and Stapelfeld family for their generous support of iNFixion Bioscience. Their partnership helps fuel our mission to develop new therapies that restore healthy NF1 protein (neurofibromin) to treat and prevent symptoms of neurofibromatosis type 1 (NF1). As both researchers and NF1 parents, we’re especially thankful to have partners who […]

iNFixion Bioscience is developing an antisense oligonucleotide (ASO) therapy designed to boost NF1 protein expression, aiming to address the underlying root cause driver of neurofibromatosis type 1 (NF1) symptoms, namely NF1 protein haploinsufficiency. Following promising in vitro data, demonstrating the potential for this approach across multiple human cell types, the company has launched a seed […]

Members of iNFixion’s executive team headed to Brussels for the 2024 Global NF Conference, the leading international meeting shaping the future of neurofibromatosis and schwannomatosis research and clinical care. Organized by the Children’s Tumor Foundation and the European NF Group, this event brought together over 1,000 experts, clinicians, researchers, and advocates. The team was honored […]

iNFixion published a peer-reviewed paper in the Journal of Translational Genetics and Genomics highlighting the rationale for haploinsufficiency correction therapy (HCT) as a potential treatment for neurofibromatosis type 1 (NF1). Evidence supports that a reduced level of functional neurofibromin (NF1 protein) in cells harboring an NF1 mutation plays a direct role in driving NF1 manifestations. […]